Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/65—Tetracyclines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, particularly to the eye and eyelids.
• the invention also relates to this topical composition for its use in the treatment of bacterial infections of the skin and mucous membranes.
• Doxycycline is an antibiotic of the tetracycline family which is essentially administered orally in pharmaceutical compositions adapted for such administration, essentially tablets of different forms with different dosages of doxycycline.
• a liquid form suitable for administration in the form of intravenous infusion is also a liquid form suitable for administration in the form of intravenous infusion.
• the active ingredient is used in the form of hyclate or monohydrate.
• compositions suitable for topical application must meet strict specifications for their storage, so that the product undergoes little damage (usually less than 5%) when stored for 6 months, or up to 2 years.
• doxycycline degrades on contact with water which renders it unfit for use in the form of usual topical formulations.
• compositions with doxycycline contents greater than 1% for the treatment of ulcers and burns in patients with leprosy The application US 2006/0172982 describes compositions with more than 10% doxycycline, up to 50%, for treating and preventing infections and inflammations (allergies, colds, etc.).
• CN 10653817 discloses compositions with greater than 2% doxycycline, up to more than 20%, in powder form with particle sizes of more than 70 ⁇ .
• the invention allows a novel treatment solution for bacterial infections of the mucous membranes and skin with a topical composition of doxycycline stable over time.
• anhydrous pharmaceutical composition for topical application of doxycycline characterized in that it comprises:
• anhydrous vehicle suitable for topical application which consists of a semisolid hydrophobic material a1) selected from petrolatum alone or supplemented with lanolin, optionally mixed with a liquid hydrophobic material a2) selected from paraffin, di- or tri-esters saturated with C6-C12 fatty acids, and b) doxycycline in a form adapted to its application on the skin or mucous membranes.
• the doxycycline in a form suitable for application to the skin or mucous membranes is a doxycycline salt selected from doxycycline hyclate and doxycycline monohydrate, preferably doxycycline hyclate.
• the doxycycline in particular hyclate or monohydrate, preferably hyclate, may be b1) in a pulverulent or micronized solid form or else in solution b2) in an anhydrous polyol, preferably in liquid form at room temperature (15 ° C - 25 ° C).
• ° C) selected from glycerol, propylene glycol, triethylene glycol, butylene glycol, methylene glycol and polyethylene glycols with a molecular weight ranging from 200 to 1500 and mixtures thereof.
• the concentration of doxycycline, in particular hyclate is between 0.001% and
• the invention also relates to this topical composition for its use in the treatment of bacterial infections of the mucous membranes and skin.
• Figure 1 shows a stability curve of doxycycline hyclate at 0.1% in aqueous solution as a function of time at 25 ° C and 40 ° C.
• Figure 2 shows a stability curve of 0.1% doxycycline hyclate in glycerol solution with or without cyclodextrin as a function of time at 25 ° C.
• Figure 3 shows a stability curve of an anhydrous formulation of 0.1% doxycycline hyclate in the presence of cyclodextrin as a function of time at 25 ° C.
• the composition according to the invention is a pharmaceutical composition, that is to say a composition intended to be administered to a human or to an animal, and, consequently, meets the sanitary requirements recognized worldwide for the design and the preparation of these compositions.
• Excipients in particular, their use as the methods of analysis are known to those skilled in the pharmaceutical field, and in particular in accordance with the requirements of the pharmacopoeia, such as the European Pharmacopoeia (Ph. Eur.), The US Pharmacopeial Convention (USP) and the Japanese Pharmacopoeia (JP) in effect.
• the composition according to the invention is an anhydrous composition so as to limit the risk of degradation of the active ingredient.
• the constituents of the composition are anhydrous, that is to say having a residual moisture content of less than 0.5%, preferably less than 0.2%, measured according to the method of determination indicated by the European Pharmacopoeia in force as the method of Karl Fisher for example.
• composition according to the invention is suitable for topical application, ie for direct application to the skin and / or the mucous membranes.
• the composition according to the invention is an ophthalmic composition, intended to be applied to the eye, to the ocular mucosa or even close to the eye, on the eyelids, where the product can migrate to the eye and the ocular mucosa.
• ophthalmic composition particular attention is paid to the choice of excipients, their qualities and the methods of preparation to eliminate the risks of microbial contaminations and / or side effects such as eye irritation due to the fragility of the eye and the ocular mucosa.
• composition according to the invention is also adapted to be packaged in conventional containers of topical pharmaceutical compositions, and in particular for ophthalmic compositions, in particular tubes or flasks.
• the packaging is suitable for single-dose or multi-dose uses, possibly with or without means for determining the quantities applied. After conditioning, the composition according to the invention can be stored for several months without substantial degradation of the doxycycline.
• the semisolid hydrophobic material a1) is advantageously chosen from petrolatum, also known under the name "petrolatum” or petroleum jelly, alone or with added lanolin in usual proportions known to those skilled in the art.
• petrolatum also known under the name "petrolatum” or petroleum jelly
• lanolin in usual proportions known to those skilled in the art.
• the petrolatum / lanolin mixture is also called lanovaseline, in which lanolin can represent up to 50% of the total weight of the mixture, generally of the order of 20 to 30%.
• the semisolid hydrophobic material a1) is petroleum jelly.
• the liquid hydrophobic material a2) is chosen from paraffin, di- or tri-esters of C6-C12 fatty acids, their mixtures and their derivatives. These products used in pharmacy are well known to those skilled in the art. Saturated fatty acid di-or triesters are esters of diols or triols for which hydroxyls are esterified with a fatty acid. In particular, medium chain triglycerides (or MCTs), such as Examples are triesters of glycerol and of capric and caprylic acids, especially marketed under the names Mygliol ® 810 or 812 or Labrafac ® Lipophilic. Others include synthetic products such as fatty acid esters of C6-C12 polyethylene oxide sold under the name Labrasol ®.
• the liquid hydrophobic material a2) is paraffin.
• the weight ratio liquid hydrophobic material / semi-solid hydrophobic material is preferably from 50/50 to 0/100.
• the content of liquid hydrophobic material a2) in the mixture will depend on the properties desired for the final composition, in particular its viscosity and its ease of use, depending on whether an application is sought on the skin or on the mucous membranes, for example or the time during which the composition is to be maintained in contact with the skin or mucous membranes.
• doxyclin is in the form of a doxycycline salt selected from doxycycline hyclate and doxycycline monohydrate, preferably doxycycline hyclate.
• the doxycycline in particular the doxycycline hyclate, is in the form of solid particles b1) of suitable size for ophthalmic ointments.
• the particle size is less than or equal to 20 ⁇ .
• This particle size is measured according to the usual particle analysis methods described in the current European Pharmacopoeia, such as the laser diffraction particle size distribution technique.
• the final concentration of particulate doxycycline in the composition, in particular hyclate is between 0.001% and 1% (w / w), preferably between 0.005% and 0.5% (w / w), more preferably between 0.01% and 0.1% (m / m).
• the anhydrous vehicle suitable for topical application will advantageously consist of a mixture of hydrophobic liquid material / semi-solid hydrophobic material whose mass ratio ranges from 50/50 to 10/90.
• the doxycycline in particular the doxycycline hyclate is in the form of a solution b2) in an anhydrous polyol.
• anhydrous polyols described in the pharmacopoeias are advantageously chosen from glycerol, propylene glycol, polyethylene glycols with a molecular weight ranging from 200 to 1500 and mixtures thereof.
• Polyethylene glycols with a molecular weight ranging from 200 to 1500 are advantageously chosen from Macrogols 400, 600 and 1500.
• the polyol is glycerol.
• the concentration of doxycycline, in particular of doxycycline hyclate in the polyol ranges from 0.001% to 3.0% by weight relative to the total mass of the solution.
• the doxycycline solution in particular doxycycline hyclate in the polyol may also comprise one or more cyclodextrins.
• Cyclodextrins in pharmacopoeias are well known to those skilled in the art. Mention may in particular be made of cyclodextrins, ⁇ -cyclodextrins and hydroxypropyl-3-cyclodextrins.
• the concentration of cyclodextrins in the polyol may advantageously range from 0.01% to 4.4% by weight relative to the total mass of the solution.
• the solution comprises:
• the total doxycycline, in particular doxycycline hyclate, cyclodextrin and polyol represents 100% by weight of the solution, that is to say that the solution consists solely of doxycycline, polyol and optionally cyclodextrin.
• Such a solution is prepared according to the usual methods of preparing solutions.
• the doxycycline in particular the doxycycline hyclate, is added to the polyol with magnetic stirring until complete dissolution.
• the resulting mixture is clear.
• cyclodextrin preparation in particular doxycycline hyclate and cyclodextrin, is prepared according to the following conditions:
• the cyclodextrin is added to the polyol and stirred magnetically between 1 to 5 hours, preferably between 2 and 4 hours,
• the doxycycline is then added to the mixture and stirred magnetically between 16 and 20 hours.
• the composition is a "hydrophilic in lipophilic (H / L)" type emulsion, the doxycycline (b) solution, in particular of doxycycline hyclate in the polyol forming globules. surrounded by the anhydrous vehicle (a).
• the globules of polyol solution advantageously have a size less than or equal to 50 ⁇ , advantageously between 20 and 30 ⁇ .
• the final concentration of doxycycline, in particular hyclate, in the form of a solution in an anhydrous polyol in the topical composition according to the invention, in particular in the form of an emulsion, is between 0.001% and 1% (m / m), preferably between 0.005% and 0.5% (w / w), more preferably between 0.01% and 0.1% (w / w).
• the present invention also relates to the solution of doxycycline in a polyol as defined previously as such, in particular as a pharmaceutical composition or as an intermediate composition for the preparation of a composition pharmaceutical, more particularly for the preparation of a topical composition in the form of H / L emulsion as described above and hereinafter.
• the composition according to the invention is a composition without preservatives.
• Preservative agents generally used in topical compositions (pharmaceutical, cosmetic, etc.) to prevent their contamination by germs are well known to those skilled in the art, such as quaternary ammoniums, in particular benzalkonium chloride, dimethylbenzylammonium, cetrimide, cetylpyridinium chloride, benzododecinium bromide, benzothonium chloride, cetalkonium chloride, mercurial preservatives, such as phenylmercuric nitrate / acetate / borate, thiomersal, alcoholic preservatives, such as ethanol, chlorobutanol, benzyl alcohol, phenylethanol, phenylethyl alcohol, carboxylic acids, such as sorbic acid, phenols, in particular methyl / propyl paraben, amidines, for example chlorhexidine digluconate and / or chel
• preservative-free is meant according to the invention a composition substantially free of such preservatives to meet a "no preservatives" indication. Its preservative content is less than or equal to 10 ppm, more particularly less than or equal to 1 ppm, preferably equal to 0 ppm, no preservative included in its composition.
• the composition In the absence of preservatives, the composition must undergo a particular treatment during its preparation and its conditioning so as to avoid and prevent contamination by microorganisms (such as Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae, Pneumococci, Streptococcus faecalis , Pseudomonas aeruginosa, Serratia marcescens, Klebsiella pneumoniae, Moraxella, Corynebacterium, Acinetobacter, Escherichia coli, Haermophilus influenzae).
• microorganisms such as Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae, Pneumococci, Streptococcus faecalis , Pseudomonas aeruginosa, Serratia marcescens, Klebsiella pneumoniae, Moraxella, Coryne
• composition without preservatives according to the invention differs from a simple composition comprising the same ingredients obtained without showing any particular precautions or describing steps of the process making it possible to obtain this characteristic sterility of the compositions according to the invention, in particular ophthalmic compositions.
• the invention particularly relates to the following topical compositions:
• compositions according to the invention are carried out according to the usual methods known to those skilled in the art, in particular with the precautions required to prepare sterile and preservative-free compositions and to condition them.
• the invention also relates to the use of a composition according to the invention for its packaging in a suitable pharmaceutical container to deliver the composition for its topical application and its preservation for several months without substantial degradation of the doxycycline.
• the invention relates to a composition as defined above, for its use in the treatment of bacterial infections of the mucous membranes or the skin, in particular the eyelids and / or the ocular mucosa.
• the invention also relates to a method for treating bacterial infections of the mucous membranes or of the skin, in particular the eyelids and / or the ocular mucosa, for which an amount of at least one infection is applied to the place of infection and / or in the vicinity thereof.
• appropriate composition according to the invention that is allowed to act. The application will be renewed as needed, advantageously until the disappearance of the symptoms of the infection.
• composition will advantageously be used or the method will be advantageously used for conditions due to bacteria sensitive to tetracyclines, such as Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae, Pneumococci, Streptococcus faecalis, Pseudomonas aeruginosa, Serratia marcescens, Klebsiella pneumoniae, Moraxella, Corynebacterium, Acinetobacter, E coli, / - / aemophilus influenzae for diseases such as stye, infectious conjunctivitis, infectious keratitis, blepharitis, dysfunction of Meibomian glands, ulceris (anterior uveitis) , canaliculitis and rosacea.
• tetracyclines such as Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae, Pneumo
• the different formulations are made using a vacuum mixer equipped with a suitable dispersion system.
• hydrophobic ointment containing the dispersed solid active principle is carried out according to the following method:
• the liquid hydrophobic material / semi-solid hydrophobic material base is formulated by mixing in a water bath at 70 ° C. in order to render all the components miscible. The temperature of the mixture is lowered to 45 ° C and the hydrophobic base is transferred to the mixer whose temperature is 45 ° C.
• the doxycycline hyclate is added to the mixer and the whole is evacuated to 80%.
• the stirring of the formula is carried out for 30 minutes, at 700 rpm, at 45 ° C. and then the temperature of the whole mixture is lowered to 37 ° C.
• the ointment obtained is packaged and cooled to room temperature.
• phase A The liquid hydrophobic material / semi-solid hydrophobic material base (referred to as phase A) is formulated by mixing in a water bath at 75 ° C. so as to render all the components miscible.
• the semi-solid hydrophobic material is added directly into the mixer at 45 ° C.
• phase A The temperature of phase A is lowered to 45 ° C and then phase A is transferred to the mixer whose temperature is 45 ° C.
• phase B The doxycycline hyclate is added to the polyol (called phase B) and stirred magnetically until complete dissolution and the temperature of the solution is increased to 45 ° C.
• phase B is added to phase A with stirring to form an emulsion.
• the emulsion is stirred for 30 minutes at 700 rpm at 45 ° C. and then the temperature of the whole mixture is lowered to 37 ° C.
• the emulsion obtained is conditioned and cooled to room temperature.
• the preparation in the form of an H / L emulsion containing the active principle and the cyclodextrins in solution in the polyol is carried out according to the following method:
• phase A The liquid hydrophobic material / semi-solid hydrophobic material base (referred to as phase A) is formulated by mixing in a water bath at 75 ° C. so as to render all the components miscible.
• the semi-solid hydrophobic material is added directly into the mixer at 45 ° C.
• phase A The temperature of phase A is lowered to 45 ° C and then phase A is transferred to the mixer whose temperature is 45 ° C.
• phase B The cyclodextrin is added to the polyol (called phase B) and stirred magnetically then the doxycycline hyclate is added to phase B and stirred magnetically until complete dissolution of all the components, the temperature of the solution is increased until at 45 ° C.
• phase B is added to phase A with stirring to form an emulsion.
• the emulsion is stirred for 30 minutes at 700 rpm at 45 ° C. and the temperature of the whole mixture is lowered to 37 ° C.
• the emulsion obtained is conditioned and cooled to room temperature.
• the content of active ingredient is determined according to the following high performance liquid chromatography method:
• compositions according to the invention mark their high stability with little or no degradation of the doxycycline (taking into account the error margins of the measurements), as shown in FIG. shows figure 2.
• the semi-solid hydrophobic material used is petroleum jelly (petrolatum) and the liquid paraffin liquid hydrophobic material.
• Emulsion 1 Weighted mass
• Emulsion 5 Weighted mass

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Ophthalmology & Optometry (AREA)
• Dermatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Dispersion Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Inorganic Chemistry (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=59153076

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Family Cites Families (10)

• 2017
  • 2017-04-03 FR FR1752853A patent/FR3064482B1/fr active Active
• 2018
  • 2018-04-03 EP EP18714781.4A patent/EP3606509A1/de active Pending
  • 2018-04-03 WO PCT/EP2018/058447 patent/WO2018185078A1/fr unknown
  • 2018-04-03 CA CA3058035A patent/CA3058035A1/en active Pending
  • 2018-04-03 JP JP2019554631A patent/JP2020512997A/ja active Pending
  • 2018-04-03 US US16/498,323 patent/US11229597B2/en active Active

Also Published As

Similar Documents

Legal Events